Decreased serum DNase1-activity in patients with autoimmune liver diseases

References

• Zachou, K., P. Muratori, G. K. Koukoulis, et al. 2013. Review article: autoimmune hepatitis – current management and challenges. Aliment. Pharmacol. Ther. 38: 887–913
   PubMed Web of Science ®Google Scholar
• Gatselis, N. K., K. Zachou, G. K. Koukoulis, and G. N. Dalekos. 2015. Autoimmune hepatitis, one disease with many faces: etiopathogenetic, clinico-laboratory and histological characteristics. World J. Gastroenterol. 21: 60–83
   PubMed Web of Science ®Google Scholar
• Liaskou, E., G. M. Hirschfield, and M. E. Gershwin. 2014. Mechanisms of tissue injury in autoimmune liver diseases. Semin. Immunopathol. 36: 553–568
   PubMed Web of Science ®Google Scholar
• Czaja, A. J. 2014. Targeting apoptosis in autoimmune hepatitis. Dig. Dis. Sci. 59: 2890–2904
   PubMed Web of Science ®Google Scholar
• Kawata, K., Y. Kobayashi, M. E. Gershwin, and C. L. Bowlus. 2012. The immunophysiology and apoptosis of biliary epithelial cells: primary biliary cirrhosis and primary sclerosing cholangitis. Clin. Rev. Allergy Immunol. 43: 230–241
   PubMed Web of Science ®Google Scholar
• Tsikrikoni, A., D. S. Kyriakou, E. I. Rigopoulou, et al. 2005. Markers of cell activation and apoptosis in bone marrow mononuclear cells of patients with autoimmune hepatitis type 1 and primary biliary cirrhosis. J. Hepatol. 42: 393–399
   PubMed Web of Science ®Google Scholar
• Kishi, K., T. Yasuda, Y. Ikehara, et al. 1990. Human serum deoxyribonuclease I (DNase I) polymorphism: pattern similarities among isozymes from serum, urine, kidney, liver, and pancreas. Am. J. Hum. Genet. 47: 121–126
   PubMed Web of Science ®Google Scholar
• Shiokawa, D., and S. Tanuma. 2001. Characterization of human DNase I family endonucleases and activation of DNase gamma during apoptosis. Biochemistry. 40: 143–152
   PubMed Web of Science ®Google Scholar
• Mannherz, H. G., M. C. Peitsch, S. Zanotti, et al. 1995. A new function for an old enzyme: the role of DNase I in apoptosis. Curr. Top. Microbiol. Immunol. 198: 161–174
   PubMedGoogle Scholar
• Martinez-Valle, F., E. Balada, J. Ordi-Ros, et al. 2009. DNase 1 activity in patients with systemic lupus erythematosus: relationship with epidemiological, clinical, immunological and therapeutical features. Lupus. 18: 418–423
   PubMed Web of Science ®Google Scholar
• Munoz, L. E., C. Janko, R. A. Chaurio, et al. 2010. IgG opsonized nuclear remnants from dead cells cause systemic inflammation in SLE. Autoimmunity. 43: 232–235
   PubMed Web of Science ®Google Scholar
• Janko, C., C. Schorn, D. Weidner, et al. 2009. Treatment with DNAse I fosters binding to nec PBMC of CRP. Autoimmunity. 42: 286–288
   PubMed Web of Science ®Google Scholar
• Viard, J. P., D. Choquette, H. Chabre, et al. 1992. Anti-histone reactivity in systemic lupus erythematosus sera: a disease activity index linked to the presence of DNA: anti-DNA immune complexes. Autoimmunity. 12: 61–68
   PubMed Web of Science ®Google Scholar
• Napirei, M., H. Karsunky, B. Zevnik, et al. 2000. Features of systemic lupus erythematosus in Dnase1-deficient mice. Nat. Genet. 25: 177–181
   PubMed Web of Science ®Google Scholar
• Dittmar, M., K. Woletz, and G. J. Kahaly. 2013. Reduced DNASE1 gene expression in thyroid autoimmunity. Horm. Metab. Res. 45: 257–260
   PubMed Web of Science ®Google Scholar
• Malickova, K., D. Duricova, M. Bortlik, et al. 2011. Impaired deoxyribonuclease I activity in patients with inflammatory bowel diseases. Autoimmune Dis. 2011: 945861
   PubMedGoogle Scholar
• Fragoulis, G. E., A. G. Vakrakou, A. Papadopoulou, et al. 2015. Impaired degradation and aberrant phagocytosis of necrotic cell debris in the peripheral blood of patients with primary Sjogren's syndrome. J. Autoimmun. 56: 12–22
   PubMed Web of Science ®Google Scholar
• Hennes, E. M., M. Zeniya, A. J. Czaja, et al. 2008. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology. 48: 169–176
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver. 2015. EASL clinical practice guidelines: autoimmune hepatitis. J. Hepatol. 63: 971–1004
   PubMed Web of Science ®Google Scholar
• Zachou, K., N. Gatselis, G. Papadamou, et al. 2011. Mycophenolate for the treatment of autoimmune hepatitis: prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of treatment-naive patients. J. Hepatol. 55: 636–646
   PubMed Web of Science ®Google Scholar
• Manns, M. P., A. J. Czaja, J. D. Gorham, et al.; American Association for the Study of Liver Diseases. 2010. Diagnosis and management of autoimmune hepatitis. Hepatology. 51: 2193–2213
   PubMed Web of Science ®Google Scholar
• Kaplan, M. M., and M. E. Gershwin. 2005. Primary biliary cirrhosis. N. Engl. J. Med. 353: 1261–1273
   PubMed Web of Science ®Google Scholar
• Hirschfield, G. M., and M. E. Gershwin. 2011. Primary biliary cirrhosis: one disease with many faces. Isr. Med. Assoc. J. 13: 55–59
   PubMed Web of Science ®Google Scholar
• Zachou, K., C. Liaskos, E. Rigopoulou, et al. 2006. Presence of high avidity anticardiolipin antibodies in patients with autoimmune cholestatic liver diseases. Clin. Immunol. 119: 203–212
   PubMed Web of Science ®Google Scholar
• Gabeta, S., G. L. Norman, C. Liaskos, et al. 2007. Diagnostic relevance and clinical significance of the new enhanced performance M2 (MIT3) ELISA for the detection of IgA and IgG antimitochondrial antibodies in primary biliary cirrhosis. J. Clin. Immunol. 27: 378–387
   PubMed Web of Science ®Google Scholar
• Dickson, E. R., P. M. Grambsch, T. R. Fleming, et al. 1989. Prognosis in primary biliary cirrhosis: model for decision making. Hepatology. 10: 1–7
   PubMed Web of Science ®Google Scholar
• Pares, A., L. Caballeria, and J. Rodes. 2006. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid. Gastroenterology. 130: 715–720
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver. 2009. EASL clinical practice guidelines: management of cholestatic liver diseases. J. Hepatol. 51: 237–267
   PubMed Web of Science ®Google Scholar
• Kim, W. R., T. M. Therneau, R. H. Wiesner, et al. 2000. A revised natural history model for primary sclerosing cholangitis. Mayo Clin. Proc. 75: 688–694
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver. 2012. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J. Hepatol. 57: 167–185
   PubMed Web of Science ®Google Scholar
• European Association for Study of Liver. 2014. EASL clinical practice guidelines: management of hepatitis C virus infection. J. Hepatol. 60: 392–420
   PubMed Web of Science ®Google Scholar
• Ratziu, V., S. Bellentani, H. Cortez-Pinto, et al. 2010. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J. Hepatol. 53: 372–384
   PubMed Web of Science ®Google Scholar
• Knodell, R. G., K. G. Ishak, W. C. Black, et al. 1981. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology. 1: 431–435
   PubMed Web of Science ®Google Scholar
• Gatselis, N. K., K. Zachou, G. L. Norman, et al. 2012. IgA antibodies against deamidated gliadin peptides in patients with chronic liver diseases. Clin. Chim. Acta. 413: 1683–1688
   PubMed Web of Science ®Google Scholar
• Ludwig, J., E. R. Dickson, and G. S. McDonald. 1978. Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis). Virchows Arch. A Pathol. Anat. Histol. 379: 103–112
   PubMed Web of Science ®Google Scholar
• Dalekos, G. N., E. Makri, S. Loges, et al. 2002. Increased incidence of anti-LKM autoantibodies in a consecutive cohort of hepatitis C patients from central Greece. Eur. J. Gastroenterol. Hepatol. 14: 35–42
   PubMed Web of Science ®Google Scholar
• Dalekos, G. N., H. Wedemeyer, P. Obermayer-Straub, et al. 1999. Epitope mapping of cytochrome P4502D6 autoantigen in patients with chronic hepatitis C during alpha-interferon treatment. J. Hepatol. 30: 366–375
   PubMed Web of Science ®Google Scholar
• Vergani, D., F. Alvarez, F. B. Bianchi, et al. 2004. Liver autoimmune serology: a consensus statement from the committee for autoimmune serology of the International Autoimmune Hepatitis Group. J. Hepatol. 41: 677–683
   PubMed Web of Science ®Google Scholar
• Zachou, K., S. Gampeta, N. K. Gatselis, et al. 2015. Anti-SLA/LP alone or in combination with anti-Ro52 and fine specificity of anti-Ro52 antibodies in patients with autoimmune hepatitis. Liver Int. 35: 660–672
   PubMed Web of Science ®Google Scholar
• Gatselis, N. K., K. Zachou, G. L. Norman, et al. 2013. Clinical significance of the fluctuation of primary biliary cirrhosis-related autoantibodies during the course of the disease. Autoimmunity. 46: 471–479
   PubMed Web of Science ®Google Scholar
• Moteki, S., P. S. Leung, E. R. Dickson, et al 1996. Epitope mapping and reactivity of autoantibodies to the E2 component of 2-oxoglutarate dehydrogenase complex in primary biliary cirrhosis using recombinant 2-oxoglutarate dehydrogenase complex. Hepatology. 23: 436–444
   PubMed Web of Science ®Google Scholar
• Barker, R. N., L. P. Erwig, K. S. Hill, et al. 2002. Antigen presentation by macrophages is enhanced by the uptake of necrotic, but not apoptotic, cells. Clin. Exp. Immunol. 127: 220–225
   PubMed Web of Science ®Google Scholar
• Paludan, S. R., and A. G. Bowie. 2013. Immune sensing of DNA. Immunity. 38: 870–880
   PubMed Web of Science ®Google Scholar
• Silva, M. T. 2010. Secondary necrosis: the natural outcome of the complete apoptotic program. FEBS Lett. 584: 4491–4499
   PubMed Web of Science ®Google Scholar
• Savill, J., I. Dransfield, C. Gregory, and C. Haslett. 2002. A blast from the past: clearance of apoptotic cells regulates immune responses. Nat. Rev. Immunol. 2: 965–975
   PubMed Web of Science ®Google Scholar
• Canbay, A., S. Friedman, and G. J. Gores. 2004. Apoptosis: the nexus of liver injury and fibrosis. Hepatology. 39: 273–278
   PubMed Web of Science ®Google Scholar
• Koga, H., S. Sakisaka, M. Ohishi, et al. 1997. Nuclear DNA fragmentation and expression of Bcl-2 in primary biliary cirrhosis. Hepatology. 25: 1077–1084
   PubMed Web of Science ®Google Scholar
• Harada, K., S. Ozaki, M. E. Gershwin, and Y. Nakanuma. 1997. Enhanced apoptosis relates to bile duct loss in primary biliary cirrhosis. Hepatology. 26: 1399–1405
   PubMed Web of Science ®Google Scholar
• Fox, C. K., A. Furtwaengler, R. R. Nepomuceno, et al. 2001. Apoptotic pathways in primary biliary cirrhosis and autoimmune hepatitis. Liver. 21: 272–279
   PubMedGoogle Scholar
• Ludwig, S., H. G. Mannherz, S. Schmitt, et al. 2009. Murine serum deoxyribonuclease 1 (DNase1) activity partly originates from the liver. Int. J. Biochem. Cell Biol. 41: 1079–1093
   PubMed Web of Science ®Google Scholar
• Treichel, U., B. M. McFarlane, T. Seki, et al 1994. Demographics of anti-asialoglycoprotein receptor autoantibodies in autoimmune hepatitis. Gastroenterology. 107: 799–804
   PubMed Web of Science ®Google Scholar
• Zachou, K., K. Oikonomou, Y. Renaudineau, et al. 2012. Anti-α actinin antibodies as new predictors of response to treatment in autoimmune hepatitis type 1 . Aliment. Pharmacol. Ther. 35: 116–125
   PubMed Web of Science ®Google Scholar
• Muratori, L., M. Cataleta, P. Muratori, et al. 1998. Liver/kidney microsomal antibody type 1 and liver cytosol antibody type 1 concentrations in type 2 autoimmune hepatitis. Gut. 42: 721–726
   PubMed Web of Science ®Google Scholar
• Madaio, M. P., M. Fabbi, M. Tiso, et al. 1996. Spontaneously produced anti-DNA/DNase I autoantibodies modulate nuclear apoptosis in living cells. Eur. J. Immunol. 26: 3035–3041
   PubMed Web of Science ®Google Scholar
• Tsukumo, S.-I., and K. Yasutomo. 2004. DNaseI in pathogenesis of systemic lupus erythematosus. Clin. Immunol. 113: 14–18
   PubMed Web of Science ®Google Scholar
• Yasutomo, K., T. Horiuchi, S. Kagami, et al. 2001. Mutation of DNASE1 in people with systemic lupus erythematosus. Nat. Genet. 28: 313–314
   PubMed Web of Science ®Google Scholar
• Napirei, M., A. G. Basnakian, E. O. Apostolov, and H. G. Mannherz. 2006. Deoxyribonuclease 1 aggravates acetaminophen-induced liver necrosis in male CD-1 mice. Hepatology. 43: 297–305
   PubMed Web of Science ®Google Scholar
• Marques, P. E., A. G. Oliveira, R. V. Pereira, et al. 2015. Hepatic DNA deposition drives drug-induced liver injury and inflammation in mice. Hepatology. 61: 348–360
   PubMed Web of Science ®Google Scholar
• Eguchi, A., A. Wree, and A. E. Feldstein. 2014. Biomarkers of liver cell death. J. Hepatol. 60: 1063–1074
   PubMed Web of Science ®Google Scholar
• Denk, G., A. J. Omary, F. P. Reiter, et al. 2014. Soluble intracellular adhesion molecule, M30 and M65 as serum markers of disease activity and prognosis in cholestatic liver diseases. Hepatol. Res. 44: 1286–1298
   PubMed Web of Science ®Google Scholar
• Higuchi, H., S. F. Bronk, Y. Takikawa, et al. 2001. The bile acid glycochenodeoxycholate induces trail-receptor 2/DR5 expression and apoptosis. J. Biol. Chem. 276: 38610–38618
   PubMed Web of Science ®Google Scholar
• Lleo, A., C. Selmi, P. Invernizzi, et al. 2009. Apotopes and the biliary specificity of primary biliary cirrhosis. Hepatology. 49: 871–879
   PubMed Web of Science ®Google Scholar